|
|
|
|
New anticoagulants reviewed at US event
There are good data to support using rivaroxaban to prevent deep vein thrombosis and promising results for using it to treat venous thromboembolism (VTE).So said Michael Crouch, professor and chairman of the Department of...
|
|
|
Thrombolysis outcome not satisfactory for DVT patients
MedWire News: Patients given catheter-directed thrombolysis (CDT) for lower extremity deep vein thrombosis (DVT) should receive long-term follow-up, say Korean researchers who found a high risk for further disease.The team...
|
|
|
Ultrasonography for suspected deep vein thrombosis: how useful is single-point augmentation
McQueen AS et al.- The study demonstrates that single-point augmentation has a low sensitivity in suspected lower-limb DVT, and that the majority of undetected DVTs are isolated to the calf veins. Ultrasonography for suspected ...
|
|
|
The incidence of deep vein thrombosis in women undergoing cesarean delivery
Sia WW et al.- A lower extremity compression ultrasound was performed prior to hospital discharge. If no DVT was detected, participants were asked to return for a second ultrasound two weeks postpartum. Participants were also...
|
|
|
Sanofi-Aventis spent $1.8 million lobbying in 3Q
WASHINGTON (AP) -- Two U.S.subsidiaries of the world's No. 4 drugmaker, Sanofi-Aventis SA of France, spent more than $1.8 million in the third quarter to lobby the federal government, according to recent disclosure forms. Sanofi...
|
|
|
Sanofi-Aventis spent $1.8M lobbying in 3Q
WASHINGTON - Two U.S.subsidiaries of the world's No. 4 drugmaker, Sanofi-Aventis SA of France, spent more than $1.8 million in the third quarter to lobby the federal government, according to recent disclosure forms. Sanofi-Aventis U.S...
|
|
|
Sanofi-Aventis units spent more than $1.8 million lobbying US government in third quarter
Article Tools Smaller| Larger Text Story Tools WASHINGTON (AP) - Two U.S.subsidiaries of the world's No. 4 drugmaker, Sanofi-Aventis SA of France, spent more than $1.8 million in the third quarter to lobby the federal government,...
|
|
|
Sanofi - Aventis units spent more than $1.8 million lobbying US government in third quarter
Sanofi-Aventis units spent more than $1.8 million lobbying US government in third quarter Article Tools Smaller| Larger Text Story Tools WASHINGTON (AP) - Two U.S.subsidiaries of the world's No. 4 drugmaker, Sanofi-Aventis SA of France,...
|
|
|
Sanofi-Aventis spent $1.8M lobbying in 3Q
WASHINGTON (AP) -- Two U.S.subsidiaries of the world's No. 4 drugmaker, Sanofi-Aventis SA of France, spent more than $1.8 million in the third quarter to lobby the federal government, according to recent disclosure forms. Sanofi...
|
|
|
Sanofi-Aventis spent $1.8M lobbying in 3Q
Two U.S.subsidiaries of the world's No. 4 drugmaker, Sanofi-Aventis SA of France, spent more than $1.8 million in the third quarter to lobby the federal government, according to recent disclosure forms. Sanofi-Aventis (nyse: SNY -...
|
|
|
Health Highlights: Jan.4, 2009
'Fire-Safe' Cigarettes Required in 14 States By End of 2009 While just about every expert agrees there is no such thing as a 'safe' cigarette, at least 14 states this year will require that all cigarettes sold within their borders be 'fire...
|
|
|
Health Highlights: Jan.4, 2009
Here are some of the latest health and medical news developments, compiled by editors of HealthDay: 'Fire-Safe' Cigarettes Required in 14 States By End of 2009 While just about every expert agrees there is no such thing as a 'safe' cigarette...
|
|
|
Health Highlights: Jan. 3, 2009
Blood Clot Drug Causes Higher Death Rate in Elderly Patients, Maker Says A drug used to treat blood clots formed primarily from deep vein thrombosis or in kidney failure increases the death rate among elderly patients, its maker...
|
|
|
Health Highlights: Jan. 3, 2009
Here are some of the latest health and medical news developments, compiled by editors of HealthDay: Blood Clot Drug Causes Higher Death Rate in Elderly Patients, Maker Says A drug used to treat blood clots formed primarily from deep ...
|
|
|
MedWatch - Innohep (tinzaparin sodium) Dear Healthcare Professional Letter Issued Re: Increased Risk of Death
ROCKVILLE, Md., Dec.31, 2008-Celgene has issued a Dear Healthcare Professional letter describing a controlled clinical study suggesting that Innohep may increase the risk for death, compared to unfractionated heparin when used to treat...
|
|
|
Celgene, FDA: Doctors Should Look For Alternatives To Blood Clot Drug
The FDA posted a letter to its Web site on Wednesday from Celgene Corp.warning users of blood-clot busting drug Innohep that new findings suggest the drug may lead to death in the elderly. The letter urges doctors to suggest alternative...
|
|
|
Blood clot prevention: Surgeon General issues call to reduce deep vein thrombosis
29--In September, the Office of the Surgeon General issued a 'Call to Action' to reduce the number of cases of deep vein thrombosis and pulmonary embolism in the United States.'Deep vein thrombosis and pulmonary...
|
|
|
A pyogenic, ruptured Baker’s cyst induced by arthroscopic pressure pump irrigation
Corten K et al.- Post-steroid septic arthritis can be treated with irrigation pump assisted arthroscopic synovectomy. The high-intra-articular fluid pressures can force the pyogenic fluid into a pre-existing Bakers cyst. The cyst can...
|
|
|
Role of Sleep in Memory and Learning Elucidated in New Studies
Investigators reported new data elucidating the effects of slow-wave sleep, circadian rhythms and homeostasis, fragmented and deprived sleep, among other factors, on learning and memory.WASHINGTON - Although the purpose of sleep remains...
|
|
|
Portal Hypertension–Related Complications After Acute Portal Vein Thrombosis: Impact of Early Anticoagul
Turnes J et al.- Anticoagulation achieved recanalization in about 40% of patients. Most patients not achieving recanalization will develop gastroesophageal varices during follow-up. However, development of variceal bleeding and...
|
|
|
Studies from C.B. Coulam et al in the area of deep vein thrombosis described
- (NewsRx.com) -- According to a study from the United States, 'Problem Inherited thrombophilia has been shown to be a risk factor for cardiovascular disease including deep venous thrombosis as well as reproductive disorders including...
|
|
|
Clot-Busting 'Call to Action' Looks to Expertise o
Pharmacists have an impressive track record for improving the detection and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)-an accomplishment that apparently has not gone unnoticed by the nation's top health...
|
|
|
Significant Milestone on Path to Commercialisation of Fondaparinux
-Australian drug developer, Alchemia Limited (ASX:ACL), today announced the achievement of a significant milestone towards the commercialisation of its lead product, generic fondaparinux.As a consequence, Alchemia will receive payments...
|
|
|
Significant Milestone on Path to Commercialisation of Fondaparinux
The trigger for the payment, which is subject to confidentiality under the terms of Alchemia's commercialisation agreements with DRL, signals important progress toward the filing of the fondaparinux ANDA with the US Federal Drug...
|
|
|
Get With the Guidelines initiative improves stroke, TIA care
MedWire News: Implementing the Get With the Guidelines (GWTG)Stroke program achieves sustained improvements in care for hospitalized patients with stroke or transient ischemic attack, research shows.Simply publishing guidelines doesnt...
|
